Overview
Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, and the shock reverberated through the managed-care sector in premarket trading. The insurer’s overall results included top-line growth and an adjusted earnings beat, but beneath those headline figures the Health Benefits segment showed material margin deterioration that sparked investor concern.
Market reaction
Elevance shares were down 6.7% in premarket trade Thursday after the company reported that adjusted operating margin in its Health Benefits business fell to 3.6% from 5.0% year-over-year. The weakness in that large segment prompted declines across peers: UnitedHealth Group shares were down about 2.7% in premarket trading as investors weighed whether Elevance’s Medicaid margin pressures could be industry-wide. Molina Healthcare, a Medicaid-focused insurer, plunged as much as 9% in premarket sessions, the steepest rollback among major peers, reversing ground after reaching a 52-week high of $244.89 as recently as Tuesday. Humana slipped roughly 1.7% in premarket trading, while Centene and CVS Health fell about 4.9% and 2.3%, respectively.
Financials and guidance
On the earnings front, Elevance reported Q2 2026 revenue of $50.47 billion, an increase of 2.1% year-on-year that beat analyst consensus by 3.9%. Adjusted EPS came in at $7.45, roughly 20% above the $6.21 consensus estimate. The company also raised full-year adjusted EPS guidance to at least $27.00.
Despite the apparent strength of those headline metrics, management disclosed a material below-the-line benefit of $0.80 per share that supported the reported EPS figure. Excluding that one-time item, the underlying insurance business showed tangible stress.
Segment dynamics
Elevance’s largest unit, Health Benefits, saw operating profit nearly halved versus the prior year. Management attributed the decline to lagging Medicaid reimbursement rates and an ongoing repositioning of the Medicare Advantage portfolio, both of which compressed margins for the segment. The company had previously advised investors to treat 2026 as a "trough year" for Health Benefits, and the Q2 data is consistent with that guidance.
Membership trends also point to softening demand: the customer base fell to 44.95 million in Q2 from 45.42 million in the prior quarter, even as revenue per member rose.
Forward-looking considerations
Analyst expectations incorporated into consensus appear to assume meaningful slowing in core earnings capacity through the second half of the year, in part because the reported EPS was aided by a non-recurring accounting item and front-loaded profitability. Sell-side forecasts cited by the company’s report suggest revenue may decline by about 2.3% over the next 12 months, a reversal from the modest growth Elevance recorded in the quarter.
Prior to the earnings release, Elevance shares had gained roughly 22% in 2026 through Monday’s close at $426.79, reflecting a sector-wide recovery after a period in which medical loss ratios exceeded 90% for many insurers through much of 2025. The latest report provides the first significant test of that recovery.
Bottom line
Although Elevance delivered revenue growth and an adjusted EPS beat in Q2, a steep drop in Health Benefits operating margin, membership contraction and reliance on a $0.80 per-share below-the-line benefit to bolster reported EPS prompted a broad premarket selloff in managed-care stocks. The data underscore persistent pressure in Medicaid economics and ongoing portfolio adjustments in Medicare Advantage that investors will be watching closely.